North America healthcare company developing a novel proprietary, non-invasive platform based on the analysis of small-noncoding RNAs extracted from urinary exosomes. The platform is powered by a liquid biopsy urine test.
The company was looking for a partner to gain insight on the European market and shape the Go-To-Market strategy to introduce their new test in Europe.
Novoptim interviewed general practitioners, physicians, patient associations, insurance and healthcare system representatives from France, Germany, Italy, and Spain. In addition, Novoptim reached out to European KOLs in Europe.
Novoptim prepared the market landscape report presenting epidemiology, patient journey, healthcare system, insurance and path to reimbursement. Novoptim also recruited 12 top European KOLs for the Advisory Board. Novoptim designed the European clinical validation strategy and developed the European marketing plan.